Quark Pharmaceuticals last week unveiled preclinical data demonstrating that its siRNA-based wet age-related macular degeneration and diabetic macular edema therapy, dubbed PF-4523655 and currently under phase II development by partner Pfizer, does not stimulate an immune response that has been associated with similar drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a commentary at eLife, Brandeis University's Eve Marder calls on researchers to value and pursue truth.

Researchers have developed a way to quickly edit white blood cells, according to the New York Times.

In Science this week: rice gene enables plants to grow quickly in times of flooding, and more.

Education-linked genetic variants could also predict a small portion of a person's social mobility, Newsweek reports.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.